Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 20.49.
Forward PE Ratio (20.49) = Close Price ($71.51) / Consensus Forward EPS ($3.52)
FORWARD PE RATIO
20.49
SECTOR MEDIAN · HEALTHCARE
20.23
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
+1.29%
vs the sector median at left
Alcon Inc.
Market Cap
$34.88B
Forward PE Ratio
20.49
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Alcon Inc. (ALC) | $34.88B | 20.49 |
| ResMed Inc. (RMD)vs › | $34.60B | 21.19 |
| DexCom, Inc. (DXCM)vs › | $34.13B | 33.47 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $32.38B | 14.72 |
| Zoetis Inc. (ZTS)vs › | $32.15B | 12.00 |
| Biogen Inc. (BIIB)vs › | $32.10B | 17.78 |
| Centene Corp. (CNC)vs › | $31.95B | 13.60 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $31.37B | 36.35 |
| Waters Corporation (WAT)vs › | $31.00B | 28.90 |
| Medline Inc. (MDLN)vs › | $29.72B | 22.97 |
Trailing P/E
55.6
reported TTM EPS
Forward P/E
20.5
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.52 implies +170.8% EPS growth vs the reported trailing $1.30.
At today's $71.51 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $3.52 | $3.42 – $3.58 | 15 | 20.3x |
| 2027-12-31 | $4.00 | $3.87 – $4.16 | 16 | 17.9x |
| 2028-12-31 | $4.52 | $3.06 – $5.52 | 15 | 15.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
